After my successful cancer treatment-- which included a full stem cell replacement operation-- I quickly realized I would be taking a lot of drugs for the rest of my life, including some very expensive ones. I was looking at-- even with insurance (Medicare Part D, the one part of Medicare-- written and passed strictly by Republicans-- that sucks) thousands of dollars a month.
"Destiny is not a matter of chance, it is a matter of choice; it is not a thing to be waited for, it is a thing to be achieved."-William Jennings Bryan
The problem: Pallone and PelosiBack in January, when the new Democratic majority began taking over the reins of power in Congress, there was a hopeful spate of reports on drug prices-- like this one by Maureen Groppe in USA Today: Democrats examine drug prices, a first step in Congress' path t
David Dayen's piece in Monday's Intercept, Nancy Pelosi's Drug-Pricing Talks With The Trump Administration Are About Mediating Fights Between Corporate Interests, highlights her balancing the bottom lines for campaign donors at Big PhRMA and the hospital industry and leaving consumers to rot.
Prescription drug prices in the U.S. are universally hated (source).
It should be a given by now that when Trump wholesale "borrowed" all Bernie’s populist talking points-- albeit with nothing whatsoever behind them-- about cutting the prices of pharmaceuticals, he was just talking out of his ass. Trump will never force the drug manufacturers to bring prices of drugs down to the levels they are in other countries.
Trump promised to rein in drug prices. It was his only sensible campaign promise.
But the plan he announced Friday does little but add another battering ram to his ongoing economic war against America’s allies.
He calls it “American patients first,” and takes aim at what he calls “foreign freeloading.” The plan will pressure foreign countries to relax their drug price controls.
On the morning of March 14, a first-year UCLA medical student named Kayla Gu approached the microphone at a meeting of her university’s Board of Regents. Speaking in a white coat with a stethoscope around her neck, she urged the university to drop a patent claim pending at India’s high court, which the David Geffen School of Medicine filed in order to block generic production of the prostate cancer drug enzalutamide, trade name Xtandi. Though developed at UCLA with tens of millions in funding from the National Institutes of Health and the U.S.
